Advancements in Lung Cancer Precision Oncology Research and Treatments

Dear Colleagues,

Lung cancer is one of the most common malignancies and the first cause of cancer death worldwide. It is currently estimated that less than 21% of lung cancer patients are alive five years from diagnosis; this depends on several factors, including the silent clinical course of the disease leading to late diagnosis, advanced age, respiratory impairment, cardiovascular and metabolic comorbidities, histology, and others. Significant improvements in lung cancer survival have been obtained in the last decade by introducing two novel therapeutic approaches for patients affected by non-small cell lung cancer (NSCLC), a histological subtype that includes approximately 85% of lung cancers: immunotherapy and gene-targeted therapy. These treatments are based on identifying predictive biomarkers, revolutionizing daily practice in modern pathology and medical oncology, and bridging consistent survival advantages in NSCLC patients. Currently, EGFR, KRAS, BRAF, ERBB2, ALK, ROS1, MET, RET, and NTRK genetic alterations and PD-L1 immunohistochemical expression are used to make treatment decisions, and a great number of ongoing clinical trials investigate novel molecular targets, medications, treatment combinations and protocols against lung cancer. This Special Issue aims to shed light on the most recent advancements in precision oncology research and current innovations in targeted and immunological treatments against lung cancer.

Dr. Panagiotis Paliogiannis
Prof. Dr. Giuseppe Palmieri
Dr. Francesca Colonese
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.